Investing IdeasBrowse All StocksMarkets

Have your own idea? Try our Stock Screener

Header cover image

Swiss (SMI) Clinical Research and Equipment Industry Analysis

UpdatedJan 21, 2025
DataAggregated Company Financials
Companies7
  • 7D2.6%
  • 3M-0.8%
  • 1Y31.5%
  • YTDn/a

In the last week, the Clinical Research and Equipment industry is up 1.4%, with Lonza Group up 1.8%. In the same time, PolyPeptide Group was down 8.5%. In the last 12 months, the industry was up 30%. As for the next few years, earnings are expected to grow by 20% per annum.

Industry Valuation and Performance

Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 21 Jan 2025CHF 54.7bCHF 10.2bCHF 943.3m35x57.9x5.4x
Thu, 19 Dec 2024CHF 53.4bCHF 10.2bCHF 943.5m37.4x56.6x5.2x
Sat, 16 Nov 2024CHF 52.2bCHF 10.2bCHF 943.5m40.6x55.3x5.1x
Mon, 14 Oct 2024CHF 54.1bCHF 10.2bCHF 943.5m41.4x57.4x5.3x
Wed, 11 Sep 2024CHF 56.6bCHF 10.2bCHF 937.2m43.6x60.4x5.5x
Fri, 09 Aug 2024CHF 57.5bCHF 10.2bCHF 923.9m44.9x62.2x5.6x
Sun, 07 Jul 2024CHF 54.3bCHF 10.3bCHF 1.0b46.3x54.2x5.3x
Tue, 04 Jun 2024CHF 51.8bCHF 10.3bCHF 1.0b43x51.7x5x
Thu, 02 May 2024CHF 53.8bCHF 10.3bCHF 1.0b43.6x53.7x5.2x
Sat, 30 Mar 2024CHF 58.5bCHF 10.3bCHF 1.0b47x58.3x5.7x
Mon, 26 Feb 2024CHF 50.6bCHF 10.2bCHF 982.3m47.1x51.5x5x
Wed, 24 Jan 2024CHF 42.3bCHF 9.8bCHF 1.5b31.5x28.3x4.3x
Fri, 22 Dec 2023CHF 41.2bCHF 9.8bCHF 1.5b32.3x27.6x4.2x
Sun, 19 Nov 2023CHF 41.5bCHF 9.8bCHF 1.5b29.5x27.8x4.2x
Tue, 17 Oct 2023CHF 46.1bCHF 9.8bCHF 1.5b30.7x30.8x4.7x
Thu, 14 Sep 2023CHF 51.6bCHF 9.8bCHF 1.5b34.8x34.6x5.3x
Sat, 12 Aug 2023CHF 53.2bCHF 9.8bCHF 1.5b35.9x34.4x5.4x
Mon, 10 Jul 2023CHF 54.6bCHF 9.7bCHF 1.6b35.7x33.4x5.6x
Wed, 07 Jun 2023CHF 61.9bCHF 9.7bCHF 1.6b37.9x37.9x6.4x
Fri, 05 May 2023CHF 61.5bCHF 9.7bCHF 1.6b41.8x37.6x6.4x
Sun, 02 Apr 2023CHF 58.1bCHF 9.7bCHF 1.7b42x34.8x6x
Tue, 28 Feb 2023CHF 59.4bCHF 9.6bCHF 1.7b34.8x35.7x6.2x
Thu, 26 Jan 2023CHF 55.3bCHF 9.2bCHF 1.3b42.6x41.6x6x
Sat, 24 Dec 2022CHF 49.9bCHF 9.2bCHF 1.3b37x37.5x5.4x
Mon, 21 Nov 2022CHF 53.3bCHF 9.2bCHF 1.3b40.4x40.1x5.8x
Wed, 19 Oct 2022CHF 53.6bCHF 9.2bCHF 1.3b41.9x40.4x5.8x
Fri, 16 Sep 2022CHF 50.3bCHF 9.2bCHF 1.3b39.6x38.9x5.5x
Sun, 14 Aug 2022CHF 57.7bCHF 8.9bCHF 1.3b36.1x44x6.5x
Tue, 12 Jul 2022CHF 58.2bCHF 8.5bCHF 1.1b44.1x54x6.9x
Thu, 09 Jun 2022CHF 58.5bCHF 8.5bCHF 1.1b48.4x54.2x6.9x
Sat, 07 May 2022CHF 60.8bCHF 9.0bCHF 1.2b40.2x50.9x6.8x
Mon, 04 Apr 2022CHF 69.6bCHF 8.3bCHF 1.1b51.3x64.5x8.4x
Wed, 02 Mar 2022CHF 68.3bCHF 8.2bCHF 1.1b54.9x62.5x8.4x
Fri, 28 Jan 2022CHF 66.6bCHF 8.0bCHF 1.1b63.5x63.2x8.3x
Price to Earnings Ratio

63.2x


Total Market Cap: CHF 66.6bTotal Earnings: CHF 1.1bTotal Revenue: CHF 8.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Clinical Research and Equipment Industry Price to Earnings3Y Average 45.7x202320242025
Current Industry PE
  • Investors are optimistic on the Swiss Life Sciences Tools and Services industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 57.3x which is higher than its 3-year average PE of 45.7x.
  • The industry is trading close to its 3-year average PS ratio of 5.7x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have grown 11% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Comparison

How does Swiss Clinical Research and Equipment compare with similar industries?

CH Market2.80%
Healthcare0.64%
Life Sciences2.57%
Clinical Research and Equipment2.57%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 563.203.5%
+CHF 1.4b		51.0%PE71x
SFZN Siegfried HoldingCHF 987.000.8%
+CHF 34.3m		14.0%PE32.9x
BANB Bachem HoldingCHF 56.250.8%
+CHF 33.7m		-0.4%PE37.1x
SKAN SKAN GroupCHF 77.001.7%
+CHF 29.2m		-3.0%PE53.7x
TECN Tecan GroupCHF 222.600.2%
+CHF 5.1m		-31.0%PE28.2x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlans & PricingLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & EnterpriseWhat's New
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

PPGN

CHF 24.20

PolyPeptide Group

7D

-9.0%

1Y

66.9%

BANB

CHF 56.25

Bachem Holding

7D

0.8%

1Y

-0.4%

TECN

CHF 222.60

Tecan Group

7D

0.2%

1Y

-31.0%

SFZN

CHF 987.00

Siegfried Holding

7D

0.8%

1Y

14.0%

SKAN

CHF 77.00

SKAN Group

7D

1.7%

1Y

-3.0%

XLS

CHF 24.10

Xlife Sciences

7D

-8.4%

1Y

-48.1%

LONN

CHF 563.20

Lonza Group

7D

3.5%

1Y

51.0%

Market Participants Recognise Lonza Group AG's (VTX:LONN) Earnings

Nov 29
Market Participants Recognise Lonza Group AG's (VTX:LONN) Earnings